	US 11,833,152 B2
	JAK1 pathway inhibitors for the treatment of cytokine-related disorders
Michael O'Neill Montgomery, Yardley, PA (US); Ahmad Naim, Hatboro, PA (US); and Susan Snodgrass, Greenville, DE (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Jul. 19, 2021, as Appl. No. 17/379,336.
Application 17/379,336 is a continuation of application No. 16/276,157, filed on Feb. 14, 2019, granted, now 11,103,510.
Claims priority of provisional application 62/631,825, filed on Feb. 18, 2018.
Claims priority of provisional application 62/710,446, filed on Feb. 16, 2018.
Prior Publication US 2022/0040187 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/397 (2006.01); A61K 31/4427 (2006.01); A61K 31/56 (2006.01); A61K 31/519 (2006.01); A61P 37/02 (2006.01); A61K 31/4155 (2006.01); A61K 31/573 (2006.01); C07K 16/28 (2006.01); A61K 31/437 (2006.01); A61P 37/00 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 31/4155 (2013.01); A61K 31/437 (2013.01); A61K 31/573 (2013.01); A61P 37/00 (2018.01); A61P 37/02 (2018.01); C07K 16/2866 (2013.01)]

25 Claims

1. A method for treating cytokine release syndrome in a subject, said method comprising administering to the subject one or more pharmaceutical compositions each comprising a JAK1 selective pathway inhibitor which is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.